

IN THE CLAIMS:

- 1.-18. (Cancelled)
19. (Currently Amended) The method of ~~claim 18~~ claims 21 or 23, wherein the human leukocyte antigen (HLA)-DR2 haplotype comprises DRB1*1501 or DRB1*15021.
20. (Currently Amended) The method of ~~claim 18~~ claims 21 or 23, wherein the patient has chronic progressive multiple sclerosis (MS).
21. (Previously Presented) A method of predicting therapeutic efficacy of treatment of a multiple sclerosis patient with a peptide of from 7 to 46 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, comprising screening a multiple sclerosis patient for the presence of an human leukocyte antigen (HLA)-DR2 haplotype, wherein the presence of the human leukocyte antigen (HLA)-DR2 haplotype in the patient is predictive of therapeutic efficacy of treatment with the peptide.
22. (Cancelled)
23. (Previously Presented) A method of predicting therapeutic efficacy of treatment of a multiple sclerosis patient with a peptide of from 8 to 25 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, comprising screening a multiple sclerosis patient for the presence of an human leukocyte antigen (HLA)-DR2 haplotype, wherein the presence of the human leukocyte antigen (HLA)-DR2 haplotype in the patient is predictive of therapeutic efficacy of treatment with the peptide.
- 24.-25. (Cancelled)